Evidence map›Paper›PMID 39198413›Full record

ArticleBlood cancer journal2024

Increased risk of subsequent neoplasm after hematopoietic stem cell transplantation in 5-year survivors of childhood acute lymphoblastic leukemia.

Aimée S R Westerveld, Pien Roesthuis, Helena J H van der Pal, Dorine Bresters, Marc Bierings, Jacqueline Loonen, Andrica C H de Vries, Marloes Louwerens, Maria M W Koopman, Marry M van den Heuvel-Eibrink and 8 more

Abstract read
In one paragraph

Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Aimée S R Westerveld *Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. a.s.r.westerveld-6@prinsesmaximacentrum.nl.ORCID 0000-0003-3215-8964
Pien Roesthuis *Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Helena J H van der PalPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Dorine BrestersPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Marc BieringsPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Jacqueline LoonenRadboud University Medical Center, Nijmegen, The Netherlands.
Andrica C H de VriesPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Marloes LouwerensLeiden University Medical Center, Leiden, The Netherlands.
Maria M W KoopmanPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Marry M van den Heuvel-EibrinkPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Margriet van der Heiden-van der LooPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Peter HoogerbruggePrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Geert O JanssensPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Ronald R de KrijgerPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Cecile M RonckersPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0000-0003-3524-4657
Rob PietersPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0000-0003-2997-3570
Leontien C M KremerPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Jop C TeepenPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute lymphoblastic leukemia (ALL) survivors are at risk for developing subsequent neoplasms, but there is limited information on long-term risks and risk factors for both subsequent malignant neoplasms (SMNs) and subsequent non-malignant neoplasms (SNMNs). We analyzed long-term risk and risk factors for SMNs and SNMNs among 3291 5-year ALL survivors from the Dutch Childhood Cancer Survivor Study-LATER cohort (1963-2014). We calculated standardized incidence ratios (SIRs) and cumulative incidences and used multivariable Cox proportional hazard regression analyses for analyzing risk factors. A total of 97 survivors developed SMNs and 266 SNMNs. The 30-year cumulative incidence was 4.1% (95%CI: 3.5-5.3) for SMNs and 10.4%(95%CI: 8.9-12.1) for SNMNs. Risk of SMNs was elevated compared to the general population (SIR: 2.6, 95%CI: 2.1-3.1). Survivors treated with hematopoietic stem cell transplantation (HSCT) with total body irradiation (TBI) (HR:4.2, 95%CI: 2.3-7.9), and without TBI (HR:4.0,95%CI: 1.2-13.7) showed increased SMN risk versus non-transplanted survivors. Cranial radiotherapy (CRT) was also a risk factor for SMNs (HR:2.1, 95%CI: 1.4-4.0). In conclusion, childhood ALL survivors have an increased SMN risk, especially after HSCT and CRT. A key finding is that even HSCT-treated survivors without TBI treatment showed an increased SMN risk, possibly due to accompanied chemotherapy treatment. This emphasizes the need for careful follow-up of HSCT and/or CRT-treated survivors.

Indexed as

Cancer SurvivorsHematopoietic Stem Cell TransplantationNeoplasms, Second PrimaryPrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentAdultChildChild, PreschoolFemaleHumansIncidenceInfantMaleRisk FactorsYoung Adult

Identifiers

PMID39198413
PMCPMC11358316

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.